Pixium Vision is developing two different retinal implant systems that recreate artificial physiological vision by electrically stimulating the retina. The devices have been developed for profoundly blind patients suffering from retinitis pigmentation or macular degeneration. The epi-retinal version (Iris) of the implant should be filed for CE Mark in H215 and the sub-retinal implant (Prima) starts feasibility studies in 2016. Using a risk-adjusted NPV model, we value the company at €10.
21 Sep 2015
A clear vision
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A clear vision
Pixium Vision is developing two different retinal implant systems that recreate artificial physiological vision by electrically stimulating the retina. The devices have been developed for profoundly blind patients suffering from retinitis pigmentation or macular degeneration. The epi-retinal version (Iris) of the implant should be filed for CE Mark in H215 and the sub-retinal implant (Prima) starts feasibility studies in 2016. Using a risk-adjusted NPV model, we value the company at €10.